Evofem’s non-hormonal contraceptive Amphora scores attractive added benefit for bacterial infection prevention

GlobalData believes that the favourable data demonstrated in the AMPREVENCE trial will drive broader use of Amphora and provide a new market opportunity for the product with the added benefit of preventing sexually transmitted infections (STIs).